Core Insights - Bioventus reported a solid Q4 performance with revenue of $158 million, reflecting a 3% increase year-over-year and a 10% organic growth after adjusting for the Advanced Rehabilitation divestiture [7][11]. - The company highlighted strong performance in Pain Treatments, which grew 15% in Q4, driven by the DUROLANE product and a shift towards single-injection therapies [4][9]. - Management provided guidance for 2026, projecting net sales of $600–610 million and adjusted EPS of $0.73–0.77, indicating expected growth in both revenue and profitability [10][21]. International Performance - International revenue remained unchanged year-over-year in Q4, but organic growth was reported at 11% for the full year, attributed to improved commercial execution and talent additions [1]. - The timing of distributor orders impacted Q4 growth, which was noted by management [1]. Restorative Therapies - Revenue in Restorative Therapies declined by 26% due to the divestiture of Advanced Rehabilitation, but organic growth was still 10%, largely driven by strong performance from the EXOGEN product [2][9]. Surgical Solutions - Surgical Solutions saw a revenue growth of 3%, with Ultrasonics facing tough comparisons against a record high from the previous year [3]. - Generator revenue in Q4 was noted as the third-highest total ever for the company, indicating a solid foundation for future growth [3]. Pain Treatments - Pain Treatments revenue advanced by 15% in Q4, with a strong emphasis on the hyaluronic acid franchise and favorable demographics for knee osteoarthritis [4]. - The performance was significantly driven by volume, with DUROLANE leading the results [4]. Financial Performance - Adjusted EBITDA for the quarter was $37 million, a 30% increase year-over-year, with an adjusted EBITDA margin of 23%, up 490 basis points from the previous year [6][11]. - The company reported a quarterly record for cash from operations at $38 million, nearly double the prior-year quarter, contributing to a full-year cash flow of nearly $75 million, a 92% increase [13][14]. Balance Sheet and Leverage - Bioventus ended the quarter with $51 million in cash and $294 million in outstanding debt, with a reduction of $29 million in debt during the quarter [15]. - The net leverage ratio declined to below 2.5x, with expectations to be well below 2x by the end of 2026 [15]. 2026 Strategy and Investments - The company plans to allocate approximately $13 million in incremental investments across growth drivers such as PNS, PRP, Ultrasonics, and international expansion [17][18]. - Management expects the combination of PNS and PRP to contribute at least 200 basis points of growth in 2026, with further acceleration anticipated in 2027 [19]. Guidance and Expectations - For 2026, management expects Q1 to be below the implied guidance range, with growth anticipated to accelerate in Q2 and the second half of the year [22]. - The company does not anticipate any additional impact from U.S. dollar fluctuations for the year [25].

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $158 million, a 3% increase compared to the prior year, with organic growth at 10% after adjusting for the Advanced Rehabilitation divestiture [23][24] - Adjusted EBITDA increased by $8 million to $37 million, representing a 30% increase year-over-year, with an Adjusted EBITDA margin of 23%, expanding by 490 basis points [24][27] - Cash flow from operations totaled $38 million, nearly doubling compared to the fourth quarter last year, contributing to a full-year cash flow increase of 92% [28] Business Line Data and Key Metrics Changes - In the pain treatments segment, revenue grew by 15% in Q4, driven by strong volume growth of DUROLANE and account wins [25] - Surgical solutions revenue grew by 3%, with Ultrasonics facing tough comparisons to prior year capital sales [25] - Restorative therapies revenue declined by 26% due to the divestiture, but organic growth was 10% excluding this impact, driven by strong performance from EXOGEN [26] Market Data and Key Metrics Changes - The international segment's revenue remained unchanged year-over-year, but organic growth was 10%, with an overall growth of 11% for the year [26] - The company expects to continue its positive momentum in international markets due to talent additions and improved commercial execution [26] Company Strategy and Development Direction - The company aims to accelerate revenue growth while strengthening earnings power and expanding capital allocation options through consistent growth in free cash flow [6][7] - In 2026, the company plans to invest approximately $13 million in growth drivers, including PNS, PRP, Ultrasonics, and international business [13][16] - The focus will be on driving above-market growth, expanding profitability, and strengthening cash flow, with an expected EBITDA margin of approximately 20% for 2026 [19][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's transformation and its ability to deliver above-market revenue growth while increasing investments in growth drivers [20][66] - The company anticipates earnings growth to outpace revenue growth, driven by strong gross margins and disciplined resource allocation [19][30] Other Important Information - The company has refinanced its term loan, enhancing liquidity and driving interest expense savings [12] - The company expects cash from operations to range between $82 million and $87 million in 2026, an increase of approximately 10%-17% [30] Q&A Session Summary Question: Growth contribution year-over-year from price and thoughts on GELSYN-3 and SUPARTZ FX - Management indicated that growth was primarily driven by volume, with DUROLANE leading performance [34][36] Question: Assumptions by segment for 2026 growth - Pain treatments are expected to see mid to high single-digit growth, while restorative therapies are projected to grow low to mid-single digits [38][39] Question: Tailwind from favorable order timing in Q4 - Management estimated that favorable order timing contributed approximately $2 million to growth in Q4 [46] Question: Learnings from the PNS pilot phase and confirmation of 200 basis point growth - Positive feedback was received on the technology's power and ease of use, and management reaffirmed the expectation of a minimum of 200 basis points growth from PNS and PRP [48][50]

Bioventus (NasdaqGS:BVS) Q4 2025 Earnings call March 05, 2026 08:30 AM ET Company ParticipantsCaitlin Cronin - Director - MedTech Equity ResearchDave Crawford - VP of Investor Relations and TreasurerMark Singleton - SVP and CFORob Claypoole - President and CEOConference Call ParticipantsChase Knickerbocker - Senior Research AnalystMichael Petusky - Research AnalystRob ClaypooleGood day, and welcome to the Bioventus Q4 2025 earnings conference call. All participants will be in a listen-only mode. Should you ...

Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $158 million, a 3% increase compared to the prior year, with organic growth at 10% after adjusting for the impact of the Advanced Rehabilitation divestiture [20][21] - Adjusted EBITDA for the quarter was $37 million, an increase of $8 million or 30% year-over-year, with an Adjusted EBITDA margin of 23%, expanding by 490 basis points compared to the previous year [21][22] - Cash flow from operations totaled approximately $38 million, nearly doubling compared to the fourth quarter last year, contributing to a full year objective of nearly doubling cash flow from operations, achieving a 92% increase for the year [26][28] Business Line Data and Key Metrics Changes - In the pain treatments segment, revenue grew by 15% in Q4, driven by strong volume growth of DUROLANE and account wins [23] - Surgical solutions revenue increased by 3%, with Ultrasonics facing tough comparisons to prior year capital sales [23] - Restorative therapies revenue declined by 26% due to the divestiture of the Advanced Rehabilitation business, but organic growth was 10% excluding this impact [24] Market Data and Key Metrics Changes - The international segment's revenue remained unchanged compared to the prior year, with organic growth climbing 10% [24] - The international segment achieved 11% organic growth for the year, supported by a new team and improved commercial execution [24] Company Strategy and Development Direction - The company aims to accelerate revenue growth while strengthening earnings power and expanding capital allocation options through consistent growth in free cash flow [5][10] - In 2026, the company plans to invest approximately $13 million in growth drivers such as PNS, PRP, Ultrasonics, and international business [11][12] - The focus will be on driving above-market growth across core businesses, particularly the HA franchise, while also investing in marketing and R&D to support growth [11][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's transformation and strong foundation, indicating a focus on becoming a $1 billion leading med tech company [5][18] - The company anticipates earnings growth to outpace revenue growth, maintaining an EBITDA margin of approximately 20% for 2026 [17][18] - Management highlighted the importance of leveraging profitable growth to fund future growth drivers, emphasizing a long-term approach to business [40] Other Important Information - The company refinanced its term loan, enhancing liquidity and driving interest expense savings [10] - The company expects net sales for 2026 to range from $600 million to $610 million, with adjusted earnings per share projected at $0.73 to $0.77 [27][28] Q&A Session Summary Question: Growth contribution year-over-year from price in pain treatments - Management indicated that growth was primarily driven by volume, with DUROLANE leading performance [34][35] Question: Assumptions by segment for 2026 growth - Management expects low to mid-single digit growth in restorative therapies and mid to high single digit growth in the pain portfolio, with double-digit growth anticipated in surgical solutions [36][38] Question: Impact of favorable order timing in Q4 - Management estimated that favorable order timing contributed approximately $2 million to growth in Q4 [45] Question: Learnings from the PNS pilot phase - Positive feedback was received regarding the technology's power, size, and ease of use, with plans to scale the business aggressively based on these insights [48][50]

Second Quarter 2025 Performance - Second quarter revenue reached $148 million, with organic revenue growth of 6%[13] - Adjusted Earnings Per Share (EPS) increased 31% to $0.21, and Adjusted EBITDA margin increased 23%[13] - Surgical Solutions revenue increased 11% compared to the prior year quarter, driven by double-digit growth in Ultrasonics[39] - Restorative Therapies revenue declined 32% compared to the prior year quarter due to the divestiture of the Advanced Rehabilitation Business, while EXOGEN grew 11%[39] - Pain Treatments revenue increased 1% compared to the prior year quarter[39] Financial Metrics and Guidance - Adjusted Gross Margin increased 50 basis points due to improved product mix[40] - The company ended the second quarter with $33 million in cash and $341 million in debt outstanding[48] - Cash from operations was an inflow of $26 million in the second quarter[48] - The company reaffirms its 2025 financial guidance, projecting net sales in the range of $560 million to $570 million, representing organic growth of 6% to 8%[52] - Adjusted EBITDA is expected to be in the range of $112 million to $116 million, and Adjusted Earnings Per Share is projected to be in the range of $0.64 to $0.68[52] Strategic Initiatives and Future Outlook - The company received FDA 510(k) clearance for StimTrial and TalisMann, Peripheral Nerve Stimulation (PNS) products, targeting the chronic peripheral pain market[18, 20] - The PNS market is estimated to be growing above 20% annually in the U S and is expected to exceed $500 million by 2029, with an expected total addressable market of approximately $2 billion[20] - The company plans to invest in a direct sales force in the second half of 2025 and expects TalisMann and StimTrial to potentially generate $100 million or more of revenue[27] - The company forecasts at least 100 basis points of Adjusted EBITDA margin expansion in 2025[30] - The company expects cash from operations in 2025 to nearly double compared to 2024 and expects to reduce net leverage to below 2 5 times by the end of 2025[30, 48]